• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Fogarty Institute for Innovation

Why U.S. first may be the new medical device development strategy

June 6, 2017 By Chris Newmarker

Increased regulatory hurdles in Europe and China could mean more medical device development focusing on the U.S. market first. That seemed to be a major takeaway from panels on regulation and reimbursement at Healthegy’s Medtech Conference, held last week in Minneapolis. “We’re actually going to be doing more early clinical work with the FDA,” said Stacey Pugh, vice […]

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: CE Mark, China, European Union, FDA, Fogarty Institute for Innovation, healthegy, Medtronic

Edwards invests in Fogarty Institute

January 27, 2016 By Fink Densford

The Fogarty Institute for Innovation said today it received a grant from Edwards Lifesciences (NYSE:EW) to support its medical technology innovation and Lefteroff Internship programs. The programs help support next generation life sciences companies by supporting individuals, other programs and early stage ideas, the Institute said. “We are grateful to Edwards Lifesciences Foundation for their continued […]

Filed Under: Business/Financial News Tagged With: Edwards Lifesciences, Fogarty Institute for Innovation

J&J’s Ethicon backs Fogarty Institute

October 27, 2015 By Brad Perriello

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon is backing the Fogarty Institute for Innovation, a non-profit medical device incubator founded by medtech legend Dr. John Fogarty. Although financial details were not revealed, the deal calls for Ethicon to sponsor educational programming at the institute and provide leadership and mentorship to the companies it’s incubating. The organizations […]

Filed Under: Funding Roundup Tagged With: Ethicon, Fogarty Institute for Innovation, Johnson and Johnson

Fogarty Institute adds 3 new medtech startups

July 22, 2015 By Brad Perriello

The Fogarty Institute for Innovation said today that it added a trio of medical device startups to its roster: Igantia Therapeutics, Madorra and Marz Medical. Mountain View, Calif.-based Fogarty Institute said the companies are each developing treatments for women’s health. The not-for-profit institute, named for medical device legend Dr. Tom Fogarty, incubates early-stage medtech ventures, providing intellectual, […]

Filed Under: Women's Health Tagged With: Fogarty Institute for Innovation, Igantia Therapeutics, Madorra, Marz Medical

Dr. Tom Fogarty: Venture capital is dead and it’s starting to stink

November 10, 2014 By Brian Johnson Leave a Comment

Dr. Tom Fogarty: Venture is dead and it's starting to stink

In the 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that’s now the standard of care, he’s founded more than 30 medical device startups, placing him among the most prolific inventors in the biomedical space.

Forgarty is also, without a doubt, the industry’s best quote.

Filed Under: News Well Tagged With: Covidien, Fogarty Institute for Innovation, Venture Capital/Private Equity

The making of an icon | Dr. Tom Fogarty’s love-hate relationship with the FDA

March 21, 2014 By Arezu Sarvestani Leave a Comment

Dr. Tom Fogarty's love-hate relationship with the FDA

It’s been 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that’s now the standard of care. At 80, it would be a cinch for Fogarty to retire to his California vineyard and bask in the reflected glory of his accomplishments.

But Fogarty, a serial entrepreneur with more than 30 medical device startups under his belt, told MassDevice.com recently that he has no plans to slow down until he’s 6 feet under.

Filed Under: Uncategorized Tagged With: Fogarty Institute for Innovation, Innovation, MassDevice Q&A

The making of an icon | Dr. Tom Fogarty’s ‘Fog Shop’

March 21, 2014 By Arezu Sarvestani

The making of an icon | Dr. Tom Fogarty's 'Fog Shop'


It’s been 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that’s now the standard of care. At 80, it would be a cinch for Fogarty to retire to his California vineyard and bask in the reflected glory of his accomplishments.

Filed Under: Resuscitation Tagged With: Fogarty Institute for Innovation, Innovation, MassDevice Q&A

The making of an icon | Dr. Tom Fogarty’s obsession with innovation

March 21, 2014 By Arezu Sarvestani Leave a Comment

The making of an icon | Dr. Tom Fogarty's obsession with innovation


It’s been 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that’s now the standard of care. At 80, it would be a cinch for Fogarty to retire to his California vineyard and bask in the reflected glory of his accomplishments.

Filed Under: News Well Tagged With: Fogarty Institute for Innovation, Innovation, MassDevice Q&A

Dr. Tom Fogarty: My balloon catheter wouldn’t survive today’s FDA

February 18, 2014 By Arezu Sarvestani Leave a Comment

Dr. Fogarty: My balloon catheter wouldn't survive today's FDA

Superstar medical device inventor and industry legend Dr. Thomas Fogarty may have ended up in a very different place had he come up under today’s FDA.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: 510(k) reforms, Fogarty Institute for Innovation, Innovation

The “don’ts” of pitching a new technology, according to Dr. Thomas Fogarty

January 29, 2013 By MassDevice Contributors Network Leave a Comment

Thomas Fogarty

By Fletcher Wilson

This article is an excerpt from a blog post originally published on biodesignalumni.com

Filed Under: Blog, Funding Roundup, News Well Tagged With: Fogarty Institute for Innovation, Venture Capital/Private Equity

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy